Elevated Urine Leukotriene E4 Is Associated With Worse Objective Markers in Nasal Polyposis Patients.
Adult
Biomarkers
/ blood
Chronic Disease
Eosinophils
Female
Humans
Immunoglobulin E
/ blood
Leukocyte Count
Leukotriene E4
/ urine
Male
Middle Aged
Nasal Polyps
/ blood
Paranasal Sinuses
/ diagnostic imaging
Retrospective Studies
Rhinitis
/ blood
Severity of Illness Index
Sino-Nasal Outcome Test
Sinusitis
/ blood
Tomography, X-Ray Computed
AERD
Chronic rhinosinusitis
aspirin-exacerbated respiratory disease
asthma
biomarker
endotype
urine leukotriene E4
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
24
08
2020
received:
29
05
2020
accepted:
29
08
2020
pubmed:
2
10
2020
medline:
11
5
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
Urine leukotriene E4 (uLTE4) is a biomarker of leukotriene synthesis and is elevated in patients with aspirin-exacerbated respiratory disease (AERD). It can also be useful to help delineate aspirin-tolerant chronic rhinosinusitis with nasal polyposis (CRSwNP) patients from AERD patients. The purpose of this study is to determine if uLTE4 biomarker levels are associated with objective and subjective markers of disease severity in patients with CRSwNP. A retrospective analysis of CRSwNP patients who underwent uLTE4 testing was completed to determine the association of uLTE4 levels to markers of disease severity. uLTE4 levels, as well as presenting subjective (Sinonasal Outcome Test 22 [SNOT22] scores, asthma control test [ACT] scores) and objective data (Lund-Mackay CT score, spirometry and lab values) were collected. Among the 157 CRSwNP patients who met inclusion criteria, uLTE4 levels were associated with history of asthma (P < .001), aspirin sensitivity (P < .001), worse Lund-Mackay CT scores (P = .002) and other objective markers of disease severity including serum IgE (P = .05), presenting blood eosinophil level (P < .001), and the highest recorded eosinophil level (P < .001). In subgroup analysis, associations of uLTE4 to disease markers had stronger correlations in the aspirin sensitive CRSwNP group (R range 0.31-0.52) than the aspirin tolerant CRSwNP group (R range -0.30-0.24). uLTE4 levels were not associated with subjective symptom scores (SNOT22 and ACT scores). Elevated uLTE4 biomarker levels are associated with worsened objective markers of disease severity in CRSwNP patients but not patient-reported symptom measures. 3 Laryngoscope, 131:961-966, 2021.
Substances chimiques
Biomarkers
0
Immunoglobulin E
37341-29-0
Leukotriene E4
75715-89-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
961-966Informations de copyright
© 2020 The American Laryngological, Rhinological and Otological Society, Inc. "The Triological Society" and American Laryngological Association (ALA).
Références
Ramanathan M Jr, Lee WK, Spannhake EW, Lane AP. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol 2008;22:115-121.
Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 2015;135:676-681. e671.
Graefe H, Roebke C, Schafer D, Meyer JE. Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination. J Allergy (Cairo) 2012;2012:817910.
Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.
Roland LT, Nagy C, Wang H, et al. Treatment practices for aspirin-exacerbated respiratory disease: analysis of a national insurance claims database. Int Forum Allergy Rhinol 2019;9:1420-1423.
Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE investigators. European network on aspirin-induced asthma. Eur Respir J 2000;16:432-436.
Walgama ES, Hwang PH. Aspirin-exacerbated respiratory disease. Otolaryngol Clin N Am 2017;50:83-94.
Roland LT, Wang H, Mehta CC, et al. Longitudinal progression of aspirin-exacerbated respiratory disease: analysis of a national insurance claims database. Int Forum Allergy Rhinol 2019;9:1420-1423.
Rabinovitch N. Urinary leukotriene E4. Immunol Allergy Clin N Am 2007;27:651-664. vii.
Steinke JW, Negri J, Payne SC, Borish L. Biological effects of leukotriene E4 on eosinophils. Prostaglandins Leukot Essent Fatty Acids 2014;91:105-110.
Comhair SAA, Bochenek G, Baicker-Mc Kee S, et al. The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease. Respir Res 2018;19:210.
Divekar R, Hagan J, Rank M, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract 2016;4:665-670.
Divekar R, Patel N, Jin J, et al. Symptom-based clustering in chronic rhinosinusitis relates to history of aspirin sensitivity and postsurgical outcomes. J Allergy Clin Immunol Pract 2015;3:934-940. e933.
Santarelli GD, Lam KK, Han JK. Establishing urinary leukotriene E4 as a diagnostic biomarker for chronic rhinosinusitis with comorbid asthma and atopy. Otolaryngol Head Neck Surg 2019;161:764-769.
Hagan JB, Laidlaw TM, Divekar R, et al. Urinary leukotriene E4 to determine aspirin intolerance in asthma: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2017;5:990-997. e991.
Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal outcome test. Clin Otolaryngol 2009;34:447-454.
Schatz M, Sorkness CA, Li JT, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006;117:549-556.
Schatz M, Zeiger RS, Drane A, et al. Reliability and predictive validity of the asthma control test administered by telephone calls using speech recognition technology. J Allergy Clin Immunol 2007;119:336-343.
Celejewska-Wojcik N, Mastalerz L, Wojcik K, et al. Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. Pol Arch Med Wewn 2012;122:422-427.
Kennedy DW, Wright ED, Goldberg AN. Objective and subjective outcomes in surgery for chronic sinusitis. Laryngoscope 2000;110:29-31.
Vleming M, Middelweerd MJ, de Vries N. Good results of endoscopic paranasal sinus surgery for chronic or recurrent sinusitis and for nasal polyps. Ned Tijdschr Geneeskd 1993;137:1453-1456.
Hox V, Bobic S, Callebaux I, Jorissen M, Hellings PW. Nasal obstruction and smell impairment in nasal polyp disease: correlation between objective and subjective parameters. Rhinology 2010;48:426-432.
Kenny TJ, Duncavage J, Bracikowski J, Yildirim A, Murray JJ, Tanner SB. Prospective analysis of sinus symptoms and correlation with paranasal computed tomography scan. Otolaryngol Head Neck Surg 2001;125:40-43.
Krouse JH. Computed tomography stage, allergy testing, and quality of life in patients with sinusitis. Otolaryngol Head Neck Surg 2000;123:389-392.
Smith TL, Rhee JS, Loehrl TA, Burzynski ML, Laud PW, Nattinger AB. Objective testing and quality-of-life evaluation in surgical candidates with chronic rhinosinusitis. Am J Rhinol 2003;17:351-356.
Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012;119:3790-3798.
Rabinovitch N, Zhang L, Gelfand EW. Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. J Allergy Clin Immunol 2006;118:635-640.
Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. Allergy 1997;52:124-135.
Kumlin M, Stensvad F, Larsson L, Dahlen B, Dahlen SE. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy 1995;25:467-479.
Lueke AJ, Meeusen JW, Donato LJ, Gray AV, Butterfield JH, Saenger AK. Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: a marker of systemic mastocytosis. Clin Biochem 2016;49:979-982.
Asano K, Lilly CM, O'Donnell WJ, et al. Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol 1995;96:643-651.
Workman AD, Kohanski MA, Cohen NA. Biomarkers in chronic rhinosinusitis with nasal polyps. Immunol Allergy Clin N Am 2018;38:679-692.
Avdeeva K, Fokkens W. Precision medicine in chronic rhinosinusitis with nasal polyps. Curr Allergy Asthma Rep 2018;18:25.
Yip J, Monteiro E, Chan Y. Endotypes of chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2019;27:14-19.
Choby GW, Lee S. Pharmacotherapy for the treatment of asthma: current treatment options and future directions. Int Forum Allergy Rhinol 2015;5:S35-S40.
Low CM, Keogh KA, Saba ES, et al. Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies. Int Forum Allergy Rhinol 2020;10:217-222.
Bochenek G, Stachura T, Szafraniec K, et al. Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma. J Allergy Clin Immunol Pract 2018;6:528-535.
Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 2004;1:182-188.
Dong X, Nao J, Shi J, Zheng D. Predictive value of routine peripheral blood biomarkers in Alzheimer's disease. Front Aging Neurosci 2019;11:332.
Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005;20:201-210.
Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-2362.